Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Unilever plc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Unilever plc trades at $65 (market cap $137.84B). The key difference: Unilever plc is far larger — about 141× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Unilever plc pays a 3.32% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Unilever plc for 112 Days on average.
| MRVI | UL | |
|---|---|---|
Market Cap | $977.37M | $137.84B |
Volume | 2,742,564 | 2,711,415 |
Sector | Health | Consumer Staples |
52-Week High | $9.00 | $74.59 |
52-Week Low | $2.83 | $55.05 |
Typical Hold Time | 0 Days | 112 Days |
Enterprise Value | $1.08B | $162.87B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Unilever (UL) trades at $62.49, down 0.73% with a bullish technical signal despite recent earnings misses. The company shows strong profitability with 18.32% net margins and 54.56% ROE, though revenue declined to $50.5B in 2025. Recent news highlights the planned $65B food business merger with McCormick facing regulatory scrutiny while the company focuses on beauty and personal care segments.
UL presents a mixed outlook with strong fundamentals offset by execution risks. The 26.32% buy rating and $66.08 consensus target suggest modest upside potential, but investors face headwinds from competitive pressures and integration challenges from the McCormick deal. The stock's current valuation at 21.87 P/E appears reasonable given its defensive characteristics and emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
